Russell Investments Group Ltd. Acquires 59,619 Shares of Tandem Diabetes Care, Inc. $TNDM

Russell Investments Group Ltd. raised its holdings in Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 42.9% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 198,713 shares of the medical device company’s stock after buying an additional 59,619 shares during the quarter. Russell Investments Group Ltd.’s holdings in Tandem Diabetes Care were worth $3,704,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in TNDM. CWM LLC lifted its holdings in shares of Tandem Diabetes Care by 262.6% during the second quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock worth $52,000 after buying an additional 2,025 shares during the last quarter. Brooklyn Investment Group raised its stake in Tandem Diabetes Care by 417.8% during the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company’s stock valued at $65,000 after purchasing an additional 2,741 shares during the last quarter. Nisa Investment Advisors LLC boosted its holdings in Tandem Diabetes Care by 186.9% in the 2nd quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company’s stock valued at $78,000 after purchasing an additional 2,717 shares during the period. State of Wyoming grew its position in Tandem Diabetes Care by 49.1% in the 1st quarter. State of Wyoming now owns 4,467 shares of the medical device company’s stock worth $86,000 after purchasing an additional 1,471 shares during the last quarter. Finally, AlphaQuest LLC increased its holdings in shares of Tandem Diabetes Care by 819.5% during the 1st quarter. AlphaQuest LLC now owns 8,561 shares of the medical device company’s stock worth $164,000 after purchasing an additional 7,630 shares during the period.

Tandem Diabetes Care Stock Performance

Shares of NASDAQ:TNDM opened at $20.92 on Monday. The company has a debt-to-equity ratio of 2.33, a current ratio of 2.44 and a quick ratio of 1.90. The business’s fifty day moving average price is $16.52 and its two-hundred day moving average price is $15.99. Tandem Diabetes Care, Inc. has a fifty-two week low of $9.98 and a fifty-two week high of $38.28. The stock has a market capitalization of $1.42 billion, a price-to-earnings ratio of -6.86 and a beta of 1.68.

Tandem Diabetes Care (NASDAQ:TNDM) last issued its quarterly earnings data on Thursday, November 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.31). Tandem Diabetes Care had a negative return on equity of 73.97% and a negative net margin of 20.19%.The company had revenue of $249.25 million during the quarter, compared to analysts’ expectations of $235.80 million. During the same period last year, the business earned ($0.35) earnings per share. The business’s revenue was up 2.2% on a year-over-year basis. As a group, analysts predict that Tandem Diabetes Care, Inc. will post -1.68 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on the company. Citigroup reissued a “neutral” rating and set a $15.00 target price (up from $11.00) on shares of Tandem Diabetes Care in a research report on Tuesday, October 7th. Canaccord Genuity Group restated a “buy” rating and set a $24.00 price objective on shares of Tandem Diabetes Care in a research report on Monday, September 29th. Morgan Stanley set a $23.00 target price on Tandem Diabetes Care and gave the company an “equal weight” rating in a research note on Tuesday, December 2nd. Lake Street Capital downgraded shares of Tandem Diabetes Care from a “buy” rating to a “hold” rating and decreased their price target for the stock from $75.00 to $12.00 in a research note on Monday, August 11th. Finally, Stifel Nicolaus initiated coverage on shares of Tandem Diabetes Care in a report on Tuesday, October 21st. They issued a “hold” rating and a $15.00 price target on the stock. Four analysts have rated the stock with a Buy rating, twelve have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $21.63.

Tandem Diabetes Care Profile

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.